Detalles de la búsqueda
1.
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Future Oncol
; 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38415370
2.
Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study.
BMC Med Res Methodol
; 23(1): 18, 2023 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36647031
3.
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
Future Oncol
; 19(11): 775-787, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37132520
4.
A systematic review of the effectiveness of policies restricting access to pregabalin.
BMC Health Serv Res
; 17(1): 600, 2017 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28841868
5.
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Curr Med Res Opin
; 40(2): 199-207, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38078866
6.
Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data.
Curr Med Res Opin
; 40(5): 789-801, 2024 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38523576
7.
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Leuk Lymphoma
; 65(5): 660-668, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38347747
8.
Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States.
Clin Cardiol
; 46(5): 484-493, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36855960
9.
Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration.
Clin Appl Thromb Hemost
; 29: 10760296231152474, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36694957
10.
Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database.
J Interv Card Electrophysiol
; 66(3): 771-782, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35804258
11.
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Thromb Haemost
; 122(6): 926-938, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34963185
12.
Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.
PLoS One
; 17(9): e0274969, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36149864
13.
Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.
PLoS One
; 17(2): e0263903, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35176074
14.
Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
JAMA Netw Open
; 5(8): e2229333, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36044214
15.
Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer.
Curr Med Res Opin
; 37(9): 1467-1482, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34030541
16.
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.
J Clin Med
; 10(2)2021 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33429844
17.
Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Thromb Res
; 198: 163-170, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33348190
18.
Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
Adv Ther
; 38(11): 5519-5533, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34570310
19.
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Thromb Haemost
; 121(3): 383-395, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33171521
20.
Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration.
Circ Cardiovasc Qual Outcomes
; 14(11): e008005, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34724801